About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Key to New Dementia Treatments With Molecular 'Scaffold'

by Himabindu Venkatakrishnan on June 4, 2014 at 10:46 AM
Font : A-A+

 Key to New Dementia Treatments With Molecular 'Scaffold'

The manner in which molecular 'scaffold' allows key parts of cells to interact and comes apart in dementia and motor neuron disease has been discovered by researchers at King's college London, revealing a potential new target for drug discovery.

The study, published today in Nature Communications, was funded by the UK Medical Research Council, Wellcome Trust, Alzheimer's Research UK and the Motor Neurone Disease Association.

Advertisement

Researchers looked at two components of cells: mitochondria, the cell 'power houses' which produce energy for the cell; and the endoplasmic reticulum (ER) which makes proteins and stores calcium for signalling processes in the cell. ER and mitochondria form close associations and these interactions enable a number of important cell functions. However the mechanism by which ER and mitochondria become linked has not, until now, been fully understood.

Professor Chris Miller, from the Institute of Psychiatry at King's and lead author of the paper, says: "At the molecular level, many processes go wrong in dementia and motor neuron disease, and one of the puzzles we're faced with is whether there is a common pathway connecting these different processes. Our study suggests that the loosening of this 'scaffold' between the mitochondria and ER in the cell may be a key process in neurodegenerative diseases such as dementia or motor neuron disease."
Advertisement

By studying cells in a dish, the researchers discovered that an ER protein called VAPB binds to a mitochondrial protein called PTPIP51, to form a 'scaffold' enabling ER and mitochondria to form close associations. In fact, by increasing the levels of VAPB and PTPIP51, mitochondria and ER re-organised themselves to form tighter bonds.

Many of the cell's functions that are controlled by ER-mitochondria associations are disrupted in neurodegenerative diseases, so the researchers studied how the strength of this 'scaffold' was affected in these diseases. TPD-43 is a protein which is strongly linked to Amyotrophic Lateral Sclerosis (ALS, a form of motor neuron disease) and Fronto-Temporal Dementia (FTD, the second most common form of dementia), but exactly how the protein causes neurodegeneration is not properly understood.

The researchers studied how TPD-43 affected mouse cells in a dish. They found that higher levels of TPD-43 resulted in a loosening of the scaffold which reduced ER-mitochondria bonds, affecting some important cellular functions that are linked to ALS and FTD.

Professor Miller concludes: "Our findings are important in terms of advancing our understanding of basic biology, but may also provide a potential new target for developing new treatments for these devastating disorders."

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Senior Health News

 Calorie Restriction Prevents Age-Related Memory Loss
New study evaluated the effects of calorie restriction on memory in aged male Wistar rats, as well as those on brain structure changes, neurogenesis, and inflammation.
Why Do Prescription Opioids Impact Cognitive Function in Older Adults?
Seniors who received opioids over an average of 7.5 years were found to experience 20% increased chance of developing cognitive impairment.
How Does Parathyroidectomy Affect Kidney Function in Older Adults?
Physicians must discuss the probable benefit of early parathyroidectomy to decrease kidney disease risk and related complications.
 Phototherapy May Enhance Cognitive Function in Dementia
Phototherapy or exposure to bright light therapy may be one of the most promising non-pharmacological interventions that improve dementia symptoms.
 People Living Over 100 Years Own Immunity for Exceptional Longevity
Sequencing on immune cells circulating in the blood reveals the immune-specific patterns of aging and extreme human longevity in people aged over 100 years.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Key to New Dementia Treatments With Molecular 'Scaffold' Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests